Literature DB >> 338137

High dose methotrexate with citrovorum factor in adult resistant lymphoma.

S Turman, M Coleman, R T Silver, M Pasmantier.   

Abstract

Seven adult patients with advanced lymphoma, resistant to vincristine, prednisone, alkylating agents and Adriamycin were treated with "high dose" methotrexate and citrovorum factor rescue. Therapy consisted of 4 to 6-hour infusions of methotrexate (5--100 mg/kg) every 1 to 2 weeks with citrovorum rescue initiates 2 to 12 hours after termination of the infusion. Objective responses were obtained in three patients but these were short lived. Mucosal and hematologic toxicity occurred when repeat courses of therapy were administered. The results suggest that high dose methotrexate may be effective therapy in lymphoma, particularlly if citrovorum factor rescue is used early and in adequate dosage.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 338137     DOI: 10.1002/1097-0142(197712)40:6<2823::aid-cncr2820400612>3.0.co;2-2

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  2 in total

1.  An indication of possible impending toxicity during moderately high dose methotrexate infusions.

Authors:  J W Paxton; E J Stephens; H F Wood
Journal:  Br J Clin Pharmacol       Date:  1978-12       Impact factor: 4.335

2.  Therapy of primary central nervous system lymphoma with pre-irradiation methotrexate, cyclophosphamide, doxorubicin, vincristine, and dexamethasone (MCHOD).

Authors:  J Glass; C Shustik; F H Hochberg; L Cher; M L Gruber
Journal:  J Neurooncol       Date:  1996-12       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.